Oragenics IncOGEN

Oragenics Inc lost $2.2m in the first quarter of 2026, burnt $2.2m in operating cash, and still managed to keep $6.1m in the bank while spending $645k on R&D. The company’s March 31 2026 10-Q shows total assets of $7.5m, liabilities of $1.3m, and shareholders’ equity of $6.2m, with 4.3m diluted shares outstanding and a net loss per share of fifty-one cents. If that balance sheet were a person, it would be the friend who always borrows money and forgets to pay you back, yet somehow still gets invited to the pub. (source: ORAGENICS INC 10-Q (period ending 2026-03-31), SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/ex99-1.htm)

ONP-002, the company’s lead drug, is slogging through an Australian Phase IIa trial while management promises U.S. trials by 2027, a timeline that looks less like a schedule and more like a wishlist pinned to a dartboard. The May 2026 investor update repeats the same sentence structure it used a year ago-“continued to execute across all fronts-in the clinic, in the regulatory pipeline”-suggesting that execution is still a work in progress rather than a fait accompli. The same release notes that the regulatory program to bring ONP-002 to the U.S. is “actively advancing,” which in Big Pharma translates to “we have not yet received an official rebuke.” (source: Press Release dated May 18, 2026, Official product/news rail, https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/ex99-2.htm)

The company’s capital-raising plumbing is a 2024 “ATM Sales Agreement” with Dawson James Securities, later amended in January 2026 to keep the taps dripping. Under the arrangement, Oragenics can sell shares into the market over time, a tactic that keeps the lights on but rarely sets the share register ablaze. The amendment itself is a 23-word footnote that matters more to the broker’s spreadsheet than to most shareholders. (source: Amendment to Sales Agreement, dated January 22, 2026, between Oragenics, Inc. and Dawson James Securities, Inc., Official product/news rail, https://www.sec.gov/Archives/edgar/data/1174940/000149315226003237/ex1-2.htm)

Shareholder democracy arrived in the form of a 2026 proxy statement that directs investors to register online by 11:59 p.m. if they wish to attend the annual meeting, which is less a town-hall invitation and more a digital velvet rope. The proxy filing points readers to the 2025 Form 10-K hosted at a third-party proxy site, a document that summarises the business in 144 pages of regulatory prose rather than one punchy slide. (source: OGEN DEF 14A (2026-05-20), SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1174940/000149315226024605/formdefa14a.htm)

The SEC’s companyfacts JSON for Oragenics shows repeated Form 10-Q and 10-K filings, but the data rails do not yet include a 2026 annual report; until one lands, investors are left parsing quarterly drips rather than a full-year narrative. The JSON feed confirms the filing index and the submission metadata, yet offers no shortcut to the story that really matters: when, or if, ONP-002 will show statistically significant efficacy. (source: OGEN SEC companyfacts JSON (CIK 0001174940), SEC EDGAR, https://data.sec.gov/api/xbrl/companyfacts/CIK0001174940.json)

TradingView shows the instrument under the symbol OGEN, but the evidence rail supplies no price levels, volume profiles, or chart context; the market mechanism is therefore visible only through the company’s filings and not through any price data supplied here. Until a deeper data feed arrives, the share price is a spectator sport rather than a charted thesis. (source: TradingView rail, https://www.tradingview.com/symbols/NASDAQ-OGEN/)